Savara (NASDAQ:SVRA)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued on Thursday.
The analysts wrote, “Valuation and risks to achievement of target price. Our price target of $22/share is based on an equally weighted composite of: (a) $22/share, as a 30x multiple of taxed and diluted $5.47 discounted back to FY18 at 25% (in line with the expected PE multiple and discount rate of an early development stage biotechnology company); and (b) an NPV of $22/share (discounted cash flow analysis using a 14% discount rate and 2% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).””
Several other equities research analysts have also recently weighed in on SVRA. BidaskClub cut shares of Savara from a “buy” rating to a “hold” rating in a research report on Wednesday, August 15th. Zacks Investment Research upgraded shares of Savara from a “sell” rating to a “hold” rating in a research report on Thursday, July 26th. Canaccord Genuity set a $25.00 price objective on shares of Savara and gave the stock a “buy” rating in a research report on Thursday, August 2nd. Finally, Roth Capital began coverage on shares of Savara in a research report on Monday, August 13th. They set a “neutral” rating and a $12.00 price objective for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $26.80.
Savara (NASDAQ:SVRA) last released its quarterly earnings results on Wednesday, November 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.03). On average, research analysts predict that Savara will post -1.41 EPS for the current year.
In other news, CFO David L. Lowrance sold 18,480 shares of the stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $9.22, for a total transaction of $170,385.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 6.10% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Metropolitan Life Insurance Co. NY acquired a new stake in Savara in the second quarter worth $104,000. Alliancebernstein L.P. acquired a new stake in Savara in the third quarter worth $118,000. UBS Group AG grew its holdings in Savara by 1,012.8% in the first quarter. UBS Group AG now owns 14,556 shares of the company’s stock worth $133,000 after purchasing an additional 13,248 shares during the period. MetLife Investment Advisors LLC acquired a new stake in Savara in the second quarter worth $148,000. Finally, Engineers Gate Manager LP acquired a new stake in Savara in the third quarter worth $198,000. Institutional investors own 41.84% of the company’s stock.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.